Photocure (PHO.OL) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Norway · ISIN NO0010000045

Price
46.70 NOK
Market cap
1.24 bn NOK
P/E (2025)
–
P/S (2025)
2.33
Dividend yield
0.00 %
Net margin
-0.29 %
Return on equity (ROE)
-0.31 %
Return on assets (ROA)
-0.21 %

Photocure financials

Fiscal year20242025
Revenue525.39 m NOK532.58 m NOK
Gross profit494.67 m NOK490.59 m NOK
Operating income20.40 m NOK-745,000.00 NOK
EBIT20.40 m NOK7.98 m NOK
Net income-3.34 m NOK-1.52 m NOK
Diluted EPS – continuing operations-0.12 NOK-0.06 NOK

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Photocure

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. It has partnership with Artera for digital pathology AI test evaluation for bladder cancer. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, other European countries, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.